Abstract

TheRandomized Trial on the Clinical Management of ASCUS and LSIL of the Uterine Cervix is designed to: 1) Determine whether human papillomavirus(HPV) testing can effectively triage women with a cytologic diagnosis of ASCUS (atypical squamous cells of undetermined significance) or LSIL (low-grade squamous intraepithelial lesion) 2) Develop clinical management guidelines and provide prognostic information for the ASCUS and LSIL diagnostic categories of the Bethesda System, and 3) Determine whether the cost of screening and treatment for the potential precursor lesions of cervical cancer can be reduced though improved triage. The Contractor shall be responsible for all aspects of the Trial involving direct contact with patients including patient outreach and recruitment, provision of screening tests and study interviews, randomization into one of three management study arms, and provision of followup and treatment based on study protocols. As a member of the Study Steering Committee, The Contractor shall assist the preparation of a Procedures Manual to include the final protocol, data systems design, and study forms. The Contractor shall cooperate with the Study's three quality control groups, consultants, Coordinating Unit, and National Cancer Institute Project Officers.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN055157-006
Application #
2879433
Study Section
Project Start
1995-09-30
Project End
2001-09-29
Budget Start
1998-09-30
Budget End
1999-09-29
Support Year
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
University of Oklahoma Health Sciences Center
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
937727907
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117

  Publications

Wilson, Lauren; Pawlita, Michael; Castle, Phillip E et al. (2014) Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection. J Infect Dis 210:448-55
Gage, Julia C; Schiffman, Mark; Solomon, Diane et al. (2013) Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities. Cancer Epidemiol Biomarkers Prev 22:1095-101
Wilson, Lauren E; Pawlita, Michael; Castle, Phillip E et al. (2013) Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study. Int J Cancer 133:2172-81
Campos, Nicole G; Castle, Philip E; Schiffman, Mark et al. (2012) Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study. Med Decis Making 32:400-27
Marks, Morgan A; Castle, Philip E; Schiffman, Mark et al. (2012) Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer. J Clin Microbiol 50:300-6
Castle, Philip E; Gravitt, Patti E; Wentzensen, Nicolas et al. (2012) A descriptive analysis of prevalent vs incident cervical intraepithelial neoplasia grade 3 following minor cytologic abnormalities. Am J Clin Pathol 138:241-6
Castle, Philip E; Gage, Julia C; Wheeler, Cosette M et al. (2011) The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy. Obstet Gynecol 118:1222-9
Castle, Philip E; Gutierrez, Erin C; Leitch, Sharon V et al. (2011) Evaluation of a new DNA test for detection of carcinogenic human papillomavirus. J Clin Microbiol 49:3029-32
Gage, Julia C; Schiffman, Mark; Solomon, Diane et al. (2010) Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. Cancer Epidemiol Biomarkers Prev 19:1668-74
Castle, Philip E; Schiffman, Mark; Wheeler, Cosette M et al. (2010) Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol 171:155-63

Showing the most recent 10 out of 17 publications